A detailed history of Columbia Advisory Partners LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Columbia Advisory Partners LLC holds 16,420 shares of ADAP stock, worth $9,687. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,420
Previous 31,420 47.74%
Holding current value
$9,687
Previous $29,000 72.41%
% of portfolio
0.01%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 13, 2025

SELL
$0.54 - $0.95 $8,100 - $14,250
-15,000 Reduced 47.74%
16,420 $8,000
Q3 2024

Oct 18, 2024

BUY
$0.92 - $1.39 $3,066 - $4,632
3,333 Added 11.87%
31,420 $29,000
Q2 2024

Jul 12, 2024

BUY
$0.83 - $1.47 $10,376 - $18,377
12,502 Added 80.22%
28,087 $27,000
Q1 2024

Apr 12, 2024

BUY
$0.7 - $1.75 $10,909 - $27,273
15,585 New
15,585 $24,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $96.4M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Columbia Advisory Partners LLC Portfolio

Follow Columbia Advisory Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Columbia Advisory Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Columbia Advisory Partners LLC with notifications on news.